The United Kingdom’s dysphagia management industry is poised for a substantial surge in revenue, with projections indicating a robust escalation from USD 232.4 million in 2023 to an estimated USD 293.3 million by 2033. This anticipated growth underscores a burgeoning demand for dysphagia management products, expected to maintain a steady Compound Annual Growth Rate (CAGR) of 2.4% over the forecast period.
In 2022, the dysphagia management market in the United Kingdom demonstrated promising momentum, with total revenue reaching USD 228.2 million. This upward trajectory is indicative of a growing recognition of the importance of effective dysphagia management solutions and an increased emphasis on enhancing patient outcomes throughout the healthcare landscape.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18263
Dysphagia, a condition characterized by difficulty swallowing, poses significant challenges for individuals and healthcare providers alike. The rise in demand for dysphagia management products reflects a commitment to addressing these challenges and improving the quality of care for patients across the UK.
“The anticipated growth in the dysphagia management industry underscores the importance of innovative solutions and comprehensive care strategies,” said FMI. “As we continue to advance our understanding of dysphagia and refine our treatment approaches, we are poised to make meaningful strides in improving patient outcomes and enhancing overall quality of life.”
With a steadfast commitment to innovation and a growing emphasis on patient-centered care, the United Kingdom is poised to lead the way in dysphagia management, driving positive change and fostering a brighter future for individuals living with swallowing difficulties.
Key Highlights of the Report:
- The UK dysphagia management market is expected to reach a value of USD 293.3 million by 2033, up from USD 232.4 million in 2023.
- The market is projected to grow at a CAGR of 2.4% over the forecast period.
- The rising prevalence of neurological disorders, structural abnormalities, and other medical conditions is a key driver of market growth.
- The increasing awareness of dysphagia among healthcare professionals and the public is also driving market growth.
- The product segment is expected to account for the largest share of the market by 2033.
- The hospitals segment is expected to be the largest end user of dysphagia management products.
Navigating the Challenges of Dysphagia Management in the UK:
Dysphagia, the medical term for difficulty swallowing, affects millions of people worldwide. In the UK, the dysphagia management market holds significant potential, driven by an aging population and rising awareness of swallowing disorders. However, navigating this complex market presents unique challenges that can impede growth.
- Regulatory hurdles: One major obstacle lies in regulatory requirements for equipment used in high-risk anatomical areas, particularly the anterior neck. The Food & Drug Administration (FDA) demands specific clearance beyond general clearance for neuromuscular stimulation/reeducation devices. This restricts companies’ ability to launch new products and technologies, hindering innovation in the field.
- Safety concerns: The FDA’s caution regarding NMES usage on the anterior neck stems from potential risks of severe harm or death if general clearance devices are used in this area. This safety concern, while crucial, can limit the adoption of potentially beneficial therapies for dysphagia management.
- Side effects of medications: Long-term use of dysphagia drugs like PPIs (proton pump inhibitors) carries its own set of risks. These drugs, though effective, have been linked to an increased risk of hip bone fractures, decreased absorption of essential nutrients, and opportunistic infections. These potential side effects warrant careful consideration and may deter some patients from opting for medication-based therapies.
- Discomfort and complications: Feeding tubes, another common intervention for dysphagia, can cause discomfort and complications like throat irritation, abdominal cramping, and digestive issues. These side effects can significantly impact patients’ quality of life and limit the long-term use of feeding tubes.
- Potential limitations of existing therapies: Despite their widespread use, PPIs and H2 blockers (another class of dysphagia medication) can cause side effects like headaches, diarrhea, and abdominal pain. Additionally, some studies suggest a potential link between long-term PPI use and certain health conditions. These limitations highlight the need for further research and development of alternative, well-tolerated treatment options for dysphagia.
Despite these challenges, the UK dysphagia management market presents significant opportunities. By addressing regulatory hurdles, developing safer technologies, and exploring alternative treatment options, companies can contribute to improved patient outcomes and sustainable market growth.
Get Customization on This Report: https://www.futuremarketinsights.com/customization-available/rep-gb-18263
Competitive Landscape:
Leading dysphagia management companies in the UK prioritise strategic alliances as they seek to develop new product lines and increase their customer base internationally. In the UK, major players are also making significant investments in R&D to create state-of-the-art dysphagia management tools.
Recent Developments in the United Kingdom Dysphagia Management Business:
- In October 2022, the United Kingdom-based company Phagenesis Ltd. launched the Phageneyx Neurostimulation System in the United States. The new system uses pharyngeal electrical stimulation to treat people with dysphagia.
- In October 2022, Eisai and Cogstate expanded their agreement for the global development and commercialization of digital cognitive assessment technologies.
- In December 2022, Astellas, Eisai, Daiichi Sankyo, and Takeda agreed to collaborate to reduce the environmental burden in the field of pharmaceutical packaging.
Key Companies Profiled:
- Abbott
- Nestlé Health Science
- Danone S.A
- Hormel Foods Corporation
- Fresenius Kabi AG
- Cipla Ltd
- Eisai Co Ltd
- Becton, Dickinson and Company (BD)
- Cook Medical Inc.
- AstraZeneca Plc.
- VitalStim UK
- Nutricia Limited
- Simply Food Solutions Limited
- Ampcare, LLC
- E2 Scientific Corp
- TheraSIP LLC
- Phagenesis
- ProvaMed®
- Kent Precision Foods Group
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/18263
United Kingdom Dysphagia Management Industry Analysis by Category:
By Product:
- Drugs (Proton Pump Inhibitors)
- Feeding Tubes
- Naso-gastric Tubes
- PEG Tubes
- Nutritional Solutions
- Thickeners
- Beverages
- Purees
- Devices
- Medical Cups
- Neuromuscular Electrical Stimulation (NEMS)
- Tactile-thermal Stimulation (TTS)
- Pharyngeal Electrical Stimulation (PES)
By Indication:
- Oropharyngeal Dysphagia
- Esophageal Dysphagia
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Specialty Clinics
By Country:
- England
- Wales
- Scotland
- Northern Ireland
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
